28/11/24 -"The decline in the NAV valuation is largely attributable to the ongoing challenges within Eurofins' biopharma segment (29% of total revenue), as clients in the Clinical trials business in North ..."
Pages
51
Language
English
Published on
28/11/24
You may also be interested by these reports :
06/08/25
Q2 2025 results showed a return to organic growth for the Adecco GBU, and a slower decline for LHH and, to a lesser extent, Akkodis, which remains ...
31/07/25
Even though H1 operating results missed street expectations, there was a massive FCF beat. Moreover, there were important – though early stage – ...
30/07/25
Securitas beat expectations in Q2 2025, with solid organic growth, supported by North America and Europe, and a broad-based improvement in operating ...
25/07/25
BV’s H1 results met consensus and our expectations on sales but slightly exceeded them on profits. Organic growth was above 6% in Q2, with strong ...